Navigation path

Pharmaceuticals - Community Register

  

Community register of medicinal products for human use


AUTHORISED  

Product information

Invented name: Levodopa-Carbidopa-Entacapone Sandoz   
Auth. number : EU/1/13/859
INN : levodopa / carbidopa / entacapone
ATC: Anatomical main group: N - Nervous system
Therapeutic subgroup: N04 - Anti-parkinson drugs
Pharmacological subgroup: N04B - Dopaminergic agents
Chemical subgroup: N04BA - Dopa and dopa derivatives
Chemical substance: N04BA03 - Levodopa, decarboxylase inhibitor and COMT inhibitor
(See WHO ATC Index)
Indication: Levodopa/Carbidopa/Entacapone Sandoz is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment
Marketing Authorisation Holder: Orion Corporation
Orionintie 1, FI-02200 Espoo, Suomi

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/11/2013 Centralised - Authorisation EMEA/H/C/2785 (2013)7953 of 11/11/2013